Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

NCT01361308 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

614

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Symptoms

Interventions

DRUG: Brisdelle (paroxetine mesylate)
DRUG: Placebo capsules

Sponsor

Noven Therapeutics